Sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and myocardial infarction undergoing percutaneous coronary intervention: A systematic review and meta-analysis by Huzaifa Ul Haq Ansari, Muhammad Ammar Samad, Eman Mahboob, Eeshal Zulfiqar, Shurjeel Uddin Qazi, Areeba Ahsan, Mushood Ahmed, Faizan Ahmed, Raheel Ahmed, Shafaqat Ali, Mahboob Alam, Jamal S. Rana, Gregg C. Fonarow

“…Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have shown benefits in improving cardiovascular (CV) outcomes in patients with heart failure (HF) and may mitigate symptom progression in myocardial infarction (MI). …”
Get full text

Nonsevere Hypoglycemia Episode Clinical and Economic Outcomes: A Comparison between Sulfonylurea and Sodium-Glucose Cotransporter 2 Inhibitor as Add-On to Metformin from a Canadian Perspective by Pendar Farahani

“…To estimate prevalence of NSHEs and associated economic outcomes attributable to sulfonylurea (SU) versus sodium-glucose cotransporter 2 inhibitor (SGLT2i) initiation after metformin over one year for Canadian patients with type 2 diabetes (T2DM). …”
Get full text

Study of cardiovascular risk in type 2 diabetic patients in the acute phase of the coronavirus infection and post-COVID period on the background of therapy with sodium-glucose cotransporter-2 inhibitors by N.M. Kushnarоva, O.V. Zinych, A.A. Shuprovych, K.P. Komisarenko

Subjects: Get full text

Enhanced renoprotective effects of combined glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: Real‐world evidence by Jian‐Yu Jhu, Yu‐Wei Fang, Chung‐Yen Huang, Hung‐Hsiang Liou, Mon‐Ting Chen, Ming‐Hsien Tsai

Subjects: Get full text

Risk of diabetic ketoacidosis caused by sodium glucose cotransporter-2 inhibitors in patients with type 1 diabetes: a systematic review and network meta-analysis of randomized controlled trials by Ying Liu, Shiwen Yang, Aidou Jiang, Dan Zou, Zhaoyang Chen, Na Su, Na Su

Subjects: “…sodium-glucose-cotransporter-2 (SGLT2) inhibitors…”
Get full text

Prolonged impacts of sodium glucose cotransporter-2 inhibitors on metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: a retrospective analysis through magnetic resonance imaging by Agena Suzuki, Akinori Hayashi, Satoshi Oda, Rei Fujishima, Naoya Shimizu, Kenta Matoba, Tomomi Taguchi, Takuya Toki, Takeshi Miyatsuka

Subjects: Get full text

Does Treatment with Sodium-Glucose Cotransporter-2 Inhibitors Affect Adherence to International Society Criteria for Diabetic Ketoacidosis in Adult Patients with Type 2 Diabetes?... by Aongus O’Brolchain, Joshua Maletsky, Ibrahim Mian, Serena Edwards

Get full text

Impact of dapagliflozin on metabolic phenotype, hormone levels, and fertility in female mice after prolonged high-fat diet by Xiaolin Chen, Zhuoni Xiao, Na Dai, Mingxia Fan

Subjects: “…sodium-glucose cotransporter 2…”
Get full text

The immunohistochemical combination of low SGLT2 expression and high PRDX4 expression independently predicts shortened survival in patients undergoing surgical resection for hepato... by Yao Liu, Jia Han, Akihiro Shioya, Yang-Xian Zhang, Vu Anh Dung, Takeru Oyama, Xin Guo, Qian Yang, Tohru Ito, Sohsuke Yamada

Subjects: Get full text

Euglycemic diabetic ketoacidosis associated metabolic encephalopathy caused by dapagliflozin: a rare case report by Lulu Chu, Zhenhua Xi, Runzhi Ma, Weiliang Shi, Guoshen Yu

Subjects: Get full text

The Comparison of the Kidney Effects of Dipeptidyl Peptidase 4 Inhibitors and Glucagon-Like Peptide 1 Agonist-Administered Concomitant with Sodium-Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease by Kazuo Kobayashi, Masao Toyoda, Nobuo Hatori, Kazuyoshi Sato, Masaaki Miyakawa, Kouichi Tamura, Akira Kanamori

Get full text

Comparing the Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists with Sodium-Glucose Cotransporter 2 Inhibitors for Obese Type 2 Diabetes Patients Uncontrolled on Metformin: A Systematic Review and Meta-Analysis of Randomized Clinical Trials by Lu Ding, Bang Sun, Xinhua Xiao

“…To conduct the first meta-analysis of randomized controlled trials (RCTs) comparing glucagon-like peptide 1 receptor agonists (GLP-1RAs) with sodium-glucose cotransporter 2 inhibitors (SGLT-2is) for obese type 2 diabetes (T2D) patients uncontrolled on metformin. …”
Get full text

The road ahead: emerging therapies for primary IgA nephropathy by Edward J. Filippone, Rakesh Gulati, John L. Farber

Subjects: Get full text

Personalized approach in the management of women with heart failure with preserved ejection fraction and carbohydrate metabolism disorders by L.R. Petrovska, I.O. Kostitska, T.R. Petrovskyy, R.V. Petrovskyy

Subjects: Get full text

Cardiovascular Therapy Benefits of Novel Antidiabetic Drugs in Patients With Type 2 Diabetes Mellitus Complicated With Cardiovascular Disease: A Network Meta‐Analysis by Saixian Shi, Xiaofeng Li, Ye Chen, Jiahao Li, Yan Dai

Subjects: Get full text

The Association of SGLT-2 inhibitors (Empagliflozin) with the development of hypernatremic dehydration: a case report by Diana Alegre-González, Sandra García-Guerreros, Sara Martínez-Hernández, Ana Yasmina Brito-Díaz, Marta Casañas-Martínez, Ramón Baeza-Trinidad

“…Sodium-Glucose-Cotransporter -2 inhibitors (SGLT2 inhibitors) are a new class of drugs that reduce blood glucose levels by increasing glucose excretion and lowering blood pressure through natriuresis and plasma volumen contraction. …”
Get full text

Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients by Ehab Mudher Mikhael

“…New glucose-lowering classes like dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide 1 receptor agonist (GLP-1 RA), and sodium-glucose cotransporter-2 (SGLT-2) inhibitors are efficacious in controlling blood glucose level with less tendency to induce hypoglycemia and thus may constitute a good choice for diabetic patients during Ramadan. …”
Get full text

Newer Perspectives of Mechanisms for Euglycemic Diabetic Ketoacidosis by Xiaofang Yu, Saifei Zhang, Long Zhang

“…However, with the wide use of sodium glucose cotransporter 2 (SGLT-2) inhibitors, the newest class of antidiabetic agents, EDKA has come back into the spotlight. …”
Get full text

Expert Opinion on Fixed Dose Combination of Dapagliflozin Plus Sitagliptin for Unmet Cardiovascular Benefits in Type 2 Diabetes Mellitus by Soumitra Ray, J Ezhilan, Rajiv Karnik, Ashish Prasad, Rajashree Dhar

“…The fixed dose combination (FDC) of sodium-glucose cotransporter-2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors provides both glycemic and pleiotropic effects, including lower risk of hypoglycemia, lower rates of genitourinary tract infections, and weight neutrality. …”
Get full text

Euglycemic Ketoacidosis in a Patient with Metastatic Non-Small-Cell Lung Adenocarcinoma and Concomitant Pulmonary Embolism by Robert Sean O’Neill, Lauren Tyack, Mary Freeman, Hussein Soudy Hussein

“…Euglycemic ketoacidosis is a recognised side effect secondary to sodium-glucose cotransporter 2 inhibitor use in the treatment of type 2 diabetes mellitus; however, there is scarce evidence to suggest whether preexisting comorbid conditions contribute to the development of this potentially life-threatening complication. …”
Get full text